Geron GERN
NASDAQ GERN
$1.38 -0.02 (-1.78%)
As of: Sep 10, 2026 · 3:59 PM EDT

Geron (GERN) Total Non-Current Liabilities (2012 - 2026)

Geron's (GERN) quarterly Total Non-Current Liabilities came in at $191.5 million in Q2 2026, up 3.42% year-over-year from $185.1 million in Q2 2025, and down 1.63% quarter-over-quarter from $194.6 million in Q1 2026.

Analysis

Geron (GERN) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends

Geron has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $191.5 million for Q2 2026.

  • In Q2 2026, Total Non-Current Liabilities rose 3.42% year-over-year to $191.5 million; the TTM figure through Jun 2026 stood at $191.5 million (up 3.42% YoY), while the FY2025 annual figure was $232.5 million, up 11.24% from the prior year.
  • Total Non-Current Liabilities came in at $191.5 million for Q2 2026 at Geron, down from $194.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $232.5 million in Q4 2025 to a low of $183.8 million in Q1 2025.
  • Average Total Non-Current Liabilities over 3 years is $200.8 million, with a median of $194.6 million recorded in 2026.
  • Year-over-year, Total Non-Current Liabilities climbed 11.24% in 2025 and climbed 3.42% in 2026.
  • Over 3 years, Total Non-Current Liabilities stood at $209.0 million in 2024, then advanced by 11.24% to $232.5 million in 2025, then retreated by 17.66% to $191.5 million in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $191.5 million in Q2 2026, $194.6 million in Q1 2026, and $232.5 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 40.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 4.20 Bn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 12.42 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 378.37 Mn
10 Geron 914.60 Mn 613.75 Mn - 191.46 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 191.46 Mn
Mar 31, 2026 194.63 Mn
Dec 31, 2025 232.53 Mn
Sep 30, 2025 208.63 Mn
Jun 30, 2025 185.14 Mn
Mar 31, 2025 183.83 Mn
Dec 31, 2024 209.04 Mn
Dec 31, 2014 41.78 Mn
Sep 30, 2014 7.07 Mn
Jun 30, 2014 4.47 Mn
Mar 31, 2014 4.37 Mn
Dec 31, 2013 7.22 Mn
Sep 30, 2013 6.58 Mn
Jun 30, 2013 4.95 Mn
Mar 31, 2013 6.77 Mn
Dec 31, 2012 14.10 Mn